Literature DB >> 17218621

Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes.

Joo Hun Park1, Dong Soon Kim, I-Nae Park, Se Jin Jang, Masanori Kitaichi, Andrew G Nicholson, Thomas V Colby.   

Abstract

BACKGROUND: To investigate whether the better prognosis of interstitial pneumonias associated with collagen vascular disease (CVD) compared with idiopathic interstitial pneumonia (IIP) is due to higher frequency of the nonspecific interstitial pneumonia (NSIP) pattern in CVD, we compared the outcomes of patients from these two groups with the same histopathologic pattern.
SUBJECTS: The clinical features and survival of 362 patients (269 with IIP and 93 with CVD) diagnosed using surgical lung biopsy were analyzed.
RESULTS: The mean survival of the CVD group (131.0 mo) was longer than that of the IIP group (80.5 mo) (p<0.0001). The patients with usual interstitial pneumonia pattern among the CVD group (n=36) was younger, female, and predominantly nonsmoking compared with the IIP group (n=203). Although baseline lung functions were not significantly different, the CVD group survived longer (mean, 177.0 mo) than the IIP group (mean, 66.9 +/- 6.5 mo; p=0.001). By multivariate analysis, younger age, better pulmonary function, and the presence of a CVD were independent prognostic factors. In NSIP pattern, no significant differences in survival, clinical features, or lung function were found between the two groups.
CONCLUSION: Our data suggest that the better prognosis of patients in the CVD group is not solely due to the predominance of the NSIP pattern. The prognosis of patients with the usual interstitial pneumonia pattern in CVD is better than in those with idiopathic pulmonary fibrosis, despite the same pathologic pattern. In contrast, in those with an NSIP pattern, the prognosis is similar in both groups.

Entities:  

Mesh:

Year:  2007        PMID: 17218621     DOI: 10.1164/rccm.200607-912OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  124 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  Lower-lobe shrinkage relative to total lung volume in collagen vascular diseases.

Authors:  M Watanabe; T Igishi; N Burioka; J Kurai; Y Fukuoka; K Kato; A Yamasaki; Y Hasegawa; R Okazaki; E Shimizu
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

3.  Interstitial lung disease associated with anti-citrullinated peptide/protein antibody-positive anti-synthetase syndrome.

Authors:  Hideaki Yamakawa; Eri Hagiwara; Tae Iwasawa; Ryota Otoshi; Erina Tabata; Satoshi Ikeda; Ryo Okuda; Tomohisa Baba; Shinichiro Iso; Koji Okudela; Tamiko Takemura; Shinji Sato; Takashi Ogura
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 4.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

5.  Idiopathic or connective tissue disease-associated interstitial lung disease: a case of HRCT mimicry.

Authors:  Kevin R Flaherty; Dinesh Khanna
Journal:  Thorax       Date:  2014-01-06       Impact factor: 9.139

6.  Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease.

Authors:  Jeffrey J Swigris; Janelle Yorke; David B Sprunger; Christopher Swearingen; Theodore Pincus; Roland M du Bois; Kevin K Brown; Aryeh Fischer
Journal:  Respir Med       Date:  2010-05-14       Impact factor: 3.415

7.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

8.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.

Authors:  Tim Bongartz; Carlotta Nannini; Yimy F Medina-Velasquez; Sara J Achenbach; Cynthia S Crowson; Jay H Ryu; Robert Vassallo; Sherine E Gabriel; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2010-06

9.  Treating CTDs related fibrotic ILDs by immunosuppressants: "facts and faults".

Authors:  Spyros A Papiris; Konstantinos Kagouridis; Georgia Papadaki; Likurgos Kolilekas; Effrosyni D Manali
Journal:  Lung       Date:  2013-11-12       Impact factor: 2.584

Review 10.  High-resolution computed tomography in the diagnosis and follow-up of idiopathic pulmonary fibrosis.

Authors:  N Sverzellati; M De Filippo; T Bartalena; S Piciucchi; M Zompatori
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.